Home » Topics » Endocrine/metabolic, BioWorld Science

Endocrine/metabolic, BioWorld Science
RSS

Further aldose reductase inhibitors from Sankyo

June 14, 1996

Aldose reductase and AGE inhibitors from Nissan Chem.

June 14, 1996

Troglitazone selected for NIDDK study

June 14, 1996

Antidiabetic agents reported by Boehringer Mannheim

June 14, 1996

rHb1.1 phase I trials begin in end-stage renal disease

June 14, 1996

SC-55494 effective in combination with rhG-CSF

June 14, 1996

CCK-A agonists revealed by Glaxo Wellcome

June 14, 1996

Warner-Lambert seeks approval for atorvastatin

June 14, 1996

Monsanto reveals benzothiazepines with novel activity

June 14, 1996

ACAT inhibitors from Sankyo

June 14, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 10, 2026.
Ionis, AZ shares down on unexpected Wainua flop in cardiomyopathy
BioWorld
News of the unexpected phase III failure of the gene silencing drug Wainua (eplontersen) in the treatment of transthyretin-mediated amyloid cardiomyopathy sent...
FENS 2026: Next-gen biologics take on brain disease
BioWorld
Whether by fine-tuning neurotransmitter signaling or silencing disease-associated genes, emerging biologic therapies are reshaping neuroscience drug development,...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
NRF2 activators reported in Vailima Peninsula patent
BioWorld Science
Vailima Peninsula Pty Ltd. has discovered new nuclear factor erythroid 2-related factor 2 (NFE2L2; NRF2) activators potentially useful for the treatment of...